This is the authors' abstract. We don't add key points for this paper.
We aimed to investigate the long-term impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on thyroid function, cardiovascular health, renal outcomes and adverse events in individuals with obesity and without type 2 diabetes (T2D).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: